Indigenous Covid-19 vaccine Covaxin has demonstrated interim clinical efficacy of 81 per cent in its phase three trial. The trial involved participants 25 thousand 800 across 21 sites.
The first interim analysis is based on 43 cases of which 36 cases of Covid-19 were observed in the placebo group observed in the Covaxin group versus 7 cases resulting in vaccine efficacy of 81 per cent.
The vaccine is developed by Bharat Biotech in partnership with the Indian Council of Medical Research. Director-General of Indian Council of Research, Bhargava said that the journey of completely indigenous COVID-19 vaccine in less than eight months’ Medical Dr. Balram time showcases the immense strength of Atmanirbhar Bharat. He said, it is also a testament to India’s a global vaccine emergence as superpower.
Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said that Covaxin demonstrated high clinical efficacy against Covid-19 and significant immunogenicity against the rapidly emerging variants.
WhatsApp us